1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Glaucoma - Drugs In Development, 2022, provides an overview of the Glaucoma (Ophthalmology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Glaucoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Glaucoma (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Glaucoma (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 22, 23, 10, 2, 88, 28 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 5 molecules, respectively.
Glaucoma (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Glaucoma (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Glaucoma (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glaucoma (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glaucoma (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Glaucoma (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glaucoma (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glaucoma (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Glaucoma - Overview
- Glaucoma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Glaucoma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Glaucoma - Companies Involved in Therapeutics Development
- Glaucoma - Drug Profiles
- Glaucoma - Dormant Projects
- Glaucoma - Discontinued Products
- Glaucoma - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Glaucoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Glaucoma - Dormant Projects, 2022
- Glaucoma - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Glaucoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4B Technologies (Suzhou) Co Ltd
- Aadi Bioscience Inc
- AbbVie Inc
- AC Immune SA
- Adtech Pharma Inc
- Advanced Vision Technologies (New York)
- Aerie Pharmaceuticals Inc
- Amgen Inc
- Annexon Inc
- Annovis Bio Inc
- APIRx Pharmaceuticals USA LLC
- Arctic Vision Shanghai Biotechnology Co Ltd
- Astellas Pharma Inc
- Avirmax Inc
- Betaliq Inc
- Bial - Portela & Ca SA
- Biozeus Pharmaceutical SA
- Broadwing Bio
- BSIM Therapeutics SA
- Calpain Therapeutics Pty Ltd
- Cellix Bio Pvt Ltd
- Certa Therapeutics Pty Ltd
- Character Biosciences Co
- Chong Kun Dang Pharmaceutical Corp
- Cloudbreak Therapeutics LLC
- Connexin Therapeutics Inc
- Curigin Co Ltd
- D. Western Therapeutics Institute Inc
- Deha Pharmaceutical LLC
- DHP Korea Co Ltd
- Disarm Therapeutics Inc
- Dompe Farmaceutici SpA
- DTx Pharma Inc
- Emerald Organic Products Inc
- Emmecell LLC
- Evotec SE
- Eye Bio Korea Co Ltd
- EyePoint Pharmaceuticals Inc
- Eyevensys SAS
- FasT Biopharma Ltd
- Future Medicine Co Ltd
- Galimedix Therapeutics Ltd
- Glaukos Corp
- Graybug Vision Inc
- Guangzhou Cellprotek Pharmaceutical Co Ltd
- Guangzhou Magpie Pharmaceutical Co Ltd
- Gurus BioPharm Inc
- Handok Inc
- HitGen Inc
- HK inno.N Corp
- ID Pharma Co Ltd
- Iduna Therapeutics Inc
- Ildong Pharmaceutical Co Ltd
- InMed Pharmaceuticals Inc
- Intratus Inc
- Isarna Therapeutics GmbH
- jCyte Inc
- Jenivision Inc
- Kodiak Sciences Inc
- Kowa Co Ltd
- Kukje Pharmaceutical Industry Co Ltd
- Kyorin Pharmaceutical Co Ltd
- Laboratoires Thea SA
- Laboratorios Salvat SA
- Laboratorios Sophia SA de CV
- LayerBio Inc
- Lee's Pharmaceutical Holdings Ltd
- Life Biosciences LLC
- Luminus Biosciences Inc
- Matrix Biomed Inc
- MediPrint Ophthalmics Inc
- MeiraGTx Holdings Plc
- MimeTech Srl
- Mitotech SA
- MyX Therapeutics Inc
- NeurAegis Inc
- Neuraly Inc
- Neurim Pharmaceuticals Ltd
- Neurizon Pharma GBR
- Neurophth Therapeutics Inc
- Neuroptika Inc
- NeuroScientific Biopharmaceuticals Ltd
- Nexel Co Ltd
- NicOx SA
- NoNO Inc
- Novaliq GmbH
- Novartis AG
- Noveome Biotherapeutics Inc
- Novoron Bioscience Inc
- OccuRx Pty Ltd
- Ocular Therapeutix Inc
- Oculis SA
- Oculo Therapy LLC
- Ocuphire Pharma Inc
- Oncolys BioPharma Inc
- ONL Therapeutics Inc
- Perceive Biotherapeutics Inc
- pH Pharma Co Ltd
- PharmaDrug Inc
- Pinotbio Inc
- PolyActiva Pty Ltd
- Profarma
- Q BioMed Inc
- Qlaris Bio Inc
- Quark Pharmaceuticals Inc
- Qurgen Inc
- Radikal Therapeutics Inc
- Rebio Technologies Ltd
- Rebus Holdings Inc
- Regeneron Pharmaceuticals Inc
- ReNetX Bio
- Retinset SL
- Reven Holdings Inc
- Ripple therapeutics Corp
- Santen Pharmaceutical Co Ltd
- Senju Pharmaceutical Co Ltd
- SIFI SpA
- Skye Bioscience Inc
- Stuart Therapeutics Inc
- Sun Pharma Advanced Research Company Ltd
- Sun Pharmaceutical Industries Ltd
- Sustained Nano Systems LLC
- Sylentis SAU
- TaeJoon Pharmaceuticals Co Ltd
- TALLC Inc
- Tarsius Pharma Ltd
- TearClear Corp
- Teraclon IDF SL
- TikoMed AB
- Toa Eiyo Ltd
- Topadur Pharma AG
- ViSci Ltd
- Visus Therapeutics Inc
- Viva Vision Biotech
- Whitecap Biosciences LLC
- Xilingyuan Pharmaceutical Co Ltd
